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Abstract
Objectives: While off-label dosing of biologic treatments may be necessary in selected psoriasis patients, no systematic
review exists to date that synthesizes the efficacy and safety of these off-label dosing regimens. The aim of this systematic
review is to evaluate efficacy and safety of off-label dosing regimens (dose escalation, dose reduction, and interrupted
treatment) with etanercept, adalimumab, infliximab, ustekinumab, and alefacept for psoriasis treatment.
Data Sources and Study Selection: We searched OVID Medline from January 1, 1990 through August 1, 2011 for
prospective clinical trials that studied biologic therapy for psoriasis treatment in adults. Individual articles were screened for
studies that examined escalated, reduced, or interrupted therapy with etanercept, adalimumab, infliximab, ustekinumab, or
alefacept.
Data Synthesis: A total of 23 articles with 12,617 patients matched the inclusion and exclusion criteria for the systematic
review. Data were examined for primary and secondary efficacy outcomes and adverse events including infections,
malignancies, cardiovascular events, and anti-drug antibodies. The preponderance of data suggests that continuous
treatment with anti-TNF agents and anti-IL12/23 agent was necessary for maintenance of disease control. Among non-
responders, dose escalation with etanercept, adalimumab, ustekinumab, and alefacept typically resulted in greater efficacy
than standard dosing. Dose reduction with etanercept and alefacept resulted in reduced efficacy. Withdrawal of the
examined biologics led to an increase in disease activity; efficacy from retreatment did not result in equivalent initial
response rates for most biologics. Safety data on off-label dosing regimens are limited.
Conclusion: Dose escalation in non-responders generally resulted in increased efficacy in the examined biologics used to
treat moderate-to-severe psoriasis. Continuous treatment with anti-TNF agents and anti-IL12/23 agent results in superior
efficacy over interrupted therapy. The decision to use off-label dosing needs to account for both benefits and risks and be
individualized to patients’ disease severity, quality of life, and existence of comorbidities.
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Introduction
Psoriasis is a chronic, inflammatory skin disease associated with
comorbidities, psychosocial impairment, and markedly reduced
quality of life [1,2]. The condition has an estimated prevalence of
2–3% of the population worldwide, including more than
4.5 million people in the US as of 2004 [3–5]. Psoriasis is
considered an immune-mediated disorder involving T-cell activa-
tion and cytokine elaboration [6]. Recent characterization of
psoriasis immuno-pathophysiology showed that cytokines, in
particular tumor necrosis factor (TNF), interleukin-12 (IL-12)
and interleukin-23 (IL-23) represent therapeutic targets [7–11].
Biologic therapies that alter these fundamentally important
immunologic pathways in psoriasis have been developed [12].
Further, biologic drugs serve as welcomed alternatives to
traditional systemic treatments such as methotrexate and cyclo-
sporine that can be associated with cumulative, dose-dependent
toxicities [13,14].
Biologic Drugs Introduction
The safety and efficacy of etanercept, adalimumab, infliximab,
ustekinumab, and alefacept for the long-term treatment of adults
with moderate-to-severe plaque psoriasis have been previously
established in large randomized, double blind, placebo-controlled
clinical trials [15–22]. Of particular interest are the health benefits
and risks for tapering psoriasis patients off the biologic drugs
etanercept, adalimumab, infliximab, ustekinumab, and alefacept.
It is important to identify how long patients will stay in remission
following treatment cessation and to understand the clinical
characteristics associated with biologic therapy withdrawal,
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antibodies. Furthermore, it is of interest to determine whether
control of psoriasis can be recaptured with retreatment following
disease relapse.
Defining Non-Standard, Off-Label Dosing Regimens
In this systematic review, ‘‘off-label’’ or ‘‘non-standard’’ dosing
of biologics refers to any dosing regimens that are not the current
FDA-approved regimens for psoriasis treatment. The non-
standard dosing regimens are broadly categorized into (1) dose
escalation or intensification, (2) dose reduction, (3) interrupted
therapy followed by retreatment, and (4) intermittent therapy.
Specifically, dose escalation includes shortening the dosing
interval and/or increasing the amount of medication per single
dose. Similarly, dose reduction includes both lengthening of the
dosing interval and/or reduction in the amount of medication per
single dose. Interrupted treatment is defined as a withdrawal
period followed by a retreatment period with a biologic agent; the
retreatment period typically begins either at the time of disease
relapse or after a predetermined period of medication interrup-
tion. In intermittent therapy, multiple treatment cycles occur
punctuated by regular periods of non-retreatment.
Clinicians consider using non-standard dosing regimens to treat
psoriasis patients for various reasons, including patients’ unsatis-
factory response to approved regimen, changing or discontinuing
health insurance coverage, or preparing for surgeries with
significant infectious risks. Therefore, understanding the literature
on efficacy and safety of non-standard biologics dosing regimens is
crucial to clinical decision-making and care for psoriasis patients.
Aims of Systematic Review
The aims of this systematic review are (1) to determine efficacy
of off-label dosing regimens of biologic treatments in adults with
psoriasis, including dosing escalation, reduction, interruption with
retreatment, and intermittent therapy, and (2) to assess safety of
these off-label dosing regimens by examination of serious adverse
events (AEs), psoriasis rebound, and anti-drug antibodies.
Methods
Data Sources
A systematic search was performed using Ovid MEDLINE In-
Process and Ovid MEDLINE Daily from January 1, 1990 through
August 1, 2011. We searched for prospective clinical trials, which
included non-phase I/II randomized controlled clinical trials
(RCTs) and open-label extension studies that evaluated a non-
standard dosing regimen with a single biologic drug for the
treatment of moderate-to-severe plaque psoriasis in adults. Initial
identification of studies were performed using the search terms
‘‘psoriasis,’’ ‘‘etanercept,’’ ‘‘adalimumab,’’ ‘‘infliximab,’’ ‘‘usteki-
numab,’’ and ‘‘alefacept.’’ Five searches with the term ‘‘psoriasis
AND’’ each of the five biologic drugs were then conducted. These
five searches were then combined with ‘‘OR’’ in a final search.
Next, exclusion criteria were applied. Exclusion criteria included
studies that were not in English, review articles, and pediatric
evaluations. Then inclusion criteria was defined as ‘‘adults (19 plus
years),’’ ‘‘clinical trials,’’ and ‘‘randomized controlled trials.’’ Titles
and abstracts obtained from this systematic search were screened
for trials that studied biologic therapy in non-standard regimens,
which include dose escalation, dose reduction, interrupted therapy
with retreatment, or intermittent therapy.
Study Selection
Publications were selected based on five criteria: study design
(randomized controlled clinical trials, randomized trials, and
prospective open-label extension studies) study population (adults
with moderate-to-severe plaque psoriasis), intervention (non-
standard biologic drug dosing regimens as a single therapy), data
available for the primary outcomes (PASI score, PGA score, or
median time to relapse), and data available for adverse events
(serious infections, malignancy, major adverse cardiovascular
events [MACE], or anti-drug antibodies). Studies that combined
biologic treatment with other medications, such as methotrexate,
were not included in this systematic review.
Methodological Quality of Studies
We recorded several aspects of study design including
randomization, allocation concealment, groups similar at baseline,
blinding (double, single, open), inclusion of all randomized
participants, completeness of follow-up, and funding source.
Data Abstraction
Data were extracted independently by two authors (EAB and
AWA) and any disagreements were resolved by consensus. Studies
were also graded using the Grading of Recommendations
Assessment, Development and Evaluation Working Group
guidelines to provide treatment recommendations based on quality
of evidence and clinical outcomes [23].
Results
Study Selection
An initial review of the databases generated 143 publications
that matched the search criteria. After reading the abstracts of the
relevant studies, we included 23 publications with 12,617
participants in this article (Figure 1). Study characteristics and
primary and secondary outcomes for each drug are found in
Tables S1, S2, S3, S4, S5. For each trial, safety data and anti-
drug antibody data are recorded in Tables S6, S7, S8, S9, S10.
Etanercept FDA-Approved Dosing Regimen
Etanercept is a fully human dimeric fusion protein in the class of
TNF-alpha (TNF-a) inhibitors that binds both the soluble and
membrane bound TNF-a and TNF-beta (TNF-b), preventing the
cytokine from binding cell surface receptors [24]. The biologic
drug is FDA-approved as a subcutaneous (SC) injection dosed at
50 mg twice weekly (BIW) for 3 months, followed by 50 mg once
weekly (QW) for an unspecified amount of time [24]. Table S1
summarizes the outcome data for off-label dosing regimens with
etanercept from six clinical studies.
Efficacy of Etanercept Off-Label Dosing Regimens
Efficacy of Etanercept Dose Escalation. From the
literature review, two studies examined the efficacy of etanercept
dose escalation [25,26]. Cassano et al. studied dose escalation to
50 mg BIW etanercept in eight patients who did not achieve PASI
50 after 12 weeks of 50 mg QW etanercept [26]. At week 24, 75%
(6/8) of patients dosed at 50 mg BIW etanercept achieved PASI
50 and were then discontinued from etanercept treatment. At
week 36, PASI 50 was maintained by four out of these six patients
[26]. Another study investigated dose escalation to 50 mg BIW
after 12 weeks of maintenance dose at 50 mg QW etanercept if
participants satisfied 1 of 3 criteria: (1) did not achieve PASI 75
from baseline, (2) achieved PASI 75 but had significant residual
disease overall, or (3) achieved PASI 75 but had a clinically
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importance [25]. Among the 591 patients who increased
etanercept dose, the major reason was that patients did not
achieve PASI 75 (83%, 492/591) [25]. Leonardi et al. compared
the efficacy of 50 mg BIW dosing with standard 50 mg QW
dosing. Specifically, the proportion of patients on the standard
50 mg QW dosing achieving PASI 75 were 44% at baseline, 61%
at week 12, 65% at week 24, 68% at week 48, and 60% at week
72. In comparison, the proportion of patients on 50 mg BIW dose
of etanercept achieving PASI 75 were 27% at baseline, 33% at
week 12, 26% at week 24, 44% at week 48, and 43% at week 72
[25]. The proportion of patients on standard 50 mg QW
etanercept achieving PGA of ‘‘clear’’ or ‘‘‘almost clear’’ was
55%, 54%, and 51% at weeks 12, 48, and 72, respectively. In
comparison, the proportion of those on 50 mg BIW dosing
achieving ‘‘clear’’ or ‘‘almost clear’’ was 26%, 28%, and 27% at
weeks 12, 48, and 72, respectively [25].
Efficacy of Etanercept Dose Reduction. A search of the
literature identified two studies that investigated dose reduction
with etanercept [16,26]. Leonardi et al. compared 25 mg QW
etanercept and 25 mg BIW etanercept to standard induction
dosing of 50 mg BIW for 24 weeks [16]. At week 12, 14% of
patients receiving 25 mg QW therapy and 34% of those receiving
25 mg BIW therapy achieved PASI 75 compared to 49% of
patients on the standard induction dose. Similarly, at week 24,
25% of patients receiving 25 mg QW and 44% of those receiving
25 mg BIW achieved PASI 75 compared to 59% of those
receiving 50 mg BIW etanercept [16]. Cassano et al. compared 24
weeks of 50 mg QW therapy to standard induction and
maintenance dose etanercept [26]. At week 12, PASI 50 was
achieved by 75% of patients receiving 50 mg QW induction
therapy compared to 92% of patients on 50 mg BIW induction
therapy (p=0.06). Those who achieved PASI 50 at week 12 on
etanercept 50 mg QW were continued on the same dose for
another 12 weeks. At week 24, PASI 50 was achieved by 100% of
those who were continued at 50 mg QW and 100% of those who
received standard 50 mg BIW induction therapy followed by
50 mg QW maintenance etanercept [26].
Efficacy of Etanercept Withdrawal and Retreatment. After
reviewing the literature, three studies that investigated etanercept
withdrawal and retreatment were included in this article [27–29].
Gordon et al. studied a withdrawal period followed by 24 weeks of
retreatment with a randomized dose of 50 mg BIW etanercept, 25 mg
BIW etanercept, or 25 mg QW etanercept [27]. The median time to
disease relapse was reported to be 85 days, which is defined as the time
period during which at least half of the numerical improvement in
PASI that occurred in the initial 24-week treatment and follow-up
period was lost. The investigators reported that the median time to loss
of PASI 75 for patients who achieved PASI 75 during the 24-week
treatment cycle was 57 days [27]. Retreatment efficacy, defined as the
Figure 1. Summary of Systematic Review Study Selection.
doi:10.1371/journal.pone.0033486.g001
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24 week treatment cycle that achieved PASI 75 at week 12 of the
retreatment cycle, was reported to be 52% [27].
A second study by Moore et al. compared continuous versus
interrupted treatment with 50 mg QW etanercept from weeks 12
to 24 [28]. Patients identified as responders (n=917, 72.0%) were
discontinued from initial etanercept therapy at week 12 and
retreated with the original dose upon disease relapse. At week 24, a
PGA score 0 to 2, and improvement from baseline was achieved
by 71.0% of patients in the group receiving continuous therapy
and 59.5% of patients who received interrupted treatment
(p,0.0001), compared to 71.3% and 72.0% for each group,
respectively, at week 12 [28]. The investigators also found that a
PGA ‘‘clear’’ (0) or ‘‘almost clear’’ (1) status at week 12 and 24 was
achieved by 48.9% and 47.2% of patients in the continuous
treatment group, respectively, and 47.6% and 32.2% of patients in
the interrupted treatment group, at the same time intervals [28].
The mean (median) time to relapse in the interrupted group was
36.9(33.0) days and the mean (median) time to regain responder
status in patients who relapsed was 35.0(29.0) days [28].
Ortonne et al. studied etanercept retreatment in responders to
therapy after a withdrawal period [29]. At week 12 of treatment
with 50 mg BIW etanercept, responders to the regimen were
withdrawn from treatment, and administered a reduced induction
dose of 25 mg BIW etanercept upon disease relapse [29]. The
mean (SD) time to relapse was 72(46) days or about 2 months. The
authors found that 83% of responders recaptured a PGA score of 0
to 2 upon retreatment [29]. The mean time to response after
retreatment was 15 weeks, compared to 11 weeks for the initial
standard dose (p=0.001) [29].
Etanercept Safety Data
Safety data from the off-label etanercept regimens were
examined whenever available and can be found in Table S6.A
dose escalation study by Leonardi et al. showed a serious infections
rate of 1.9 events per 100 patient-years in the 50 mg BIW
compared to 0.9 events per 100 patient-years in the 50 mg QW
group [25]. Leonardi et al. also reported two (2/591) myocardial
infarctions in the 50 mg BIW group compared to zero (0/321) in
the 50 mg QW group [25].
Safety data for withdrawal-retreatment studies were also
analyzed. After a median of 85 days of etanercept withdrawal,
one case (1/85) of rebound was reported in a patient receiving
25 mg etanercept QW, which was later reversed after 4 weeks of
treatment re-initiation [27]. During the retreatment period, two
serious infections (2/103) in patients receiving etanercept 50 mg
BIW and seven unspecified serious AEs were reported [27].
Another etanercept withdrawal study reported one serious
infection (1/363) during the withdrawal period [29]. During the
retreatment period with 50 mg QW, Moore et al. reported three
internal malignancies and nine non-melanoma skin cancers
among 1,274 patients [28]. They also reported three unspecified
cases of congestive heart failure and two cases of coronary artery
disease in the interrupted treatment group [28].
Etanercept Anti-Drug Antibodies
During one dose escalation study, Leonardi et al. reported non-
neutralizing antibodies in 15.2% of patients, and the authors noted
that antibodies developed to a similar degree in both the 50 mg
BIW dose escalation group and the 50 mg QW group [25]. In a
dose reduction study by Leonardi et al., the investigators found
that 1.2% (8/652) of patients treated with etanercept at an
unspecified dose developed antibodies [16]. After a median of
85 days of withdrawal, Gordon et al. reported that 4.7% of
patients displayed low titer, non-neutralizing antibodies during the
retreatment phase [27].
Adalimumab FDA-Approved Dosing Regimen
Adalimumab is a fully human monoclonal antibody that binds
specifically to TNF-a but not TNF-b. It lyses cells that express
TNF-a on their surface in vitro [30]. Adalimumab is approved as a
SC injection for the treatment of moderate-to-severe psoriasis. The
FDA-approved standard dosing regimen for adalimumab is an
initial dose of 80 mg at week 0 that is followed by 40 mg every
other week (EOW) starting at week 1 [30]. Table S2 presents the
outcome data for off-label dosing regimens with adalimumab from
three studies.
Efficacy of Adalimumab Off-Label Dosing Regimens
Efficacy of Adalimumab Dose Escalation. One study
investigated dose escalation therapy by administering adalimumab
40 mgQWto30patientswhoachieved,PASI50duringthe initial
24-week study period [31]. After 36 weeks of treatment (from week
24 through week 60) at 40 mg QW, 17% achieved PASI 75 and
40% achieved PASI 50 [31].
Efficacy of Adalimumab Withdrawal and Retreatment. Two
trials examined withdrawal and retreatment with adalimumab
[17,32]. Menter et al. investigated withdrawal from treatment by
re-randomizing 490 patients who had achieved PASI 75
previously to adalimumab 40 mg EOW or placebo at week 33
of the study. A patient was determined to have ‘‘lost adequate
response’’ if he/she experienced ,PASI 50 response and at least
6-point increase in PASI score relative to week 33 score.
Approximately 19 weeks after randomization, 28% (68/240) of
patients who were withdrawn from adalimumab lost adequate
response compared with 5% (12/250) of participants who were
continued to adalimumab 40 mg EOW [17].
A second study evaluated the efficacy of adalimumab for
retreatment after open-label treatment and withdrawal periods
[32].Patientswhoachievedstablepsoriasiscontrolduringtheopen-
labeltreatmentperiodwerewithdrawnfromtherapyandmonitored
for relapse for up to 40 weeks. Retreatment began when a patient
relapsed or had achieved week40 without relapse. Papp et al. found
that the median timeto relapse was141 days (IQR 93–202days), or
almost 5 months [32]. Afterthe withdrawal period, patients entered
16 weeks of retreatment with adalimumab 80 mg initially followed
by40 mgEOW.Amongpatientswhohadrelapsedpriortoweek40,
69% (123/178) achieved PGA ‘‘clear’’ or ‘‘minimal’’ by the end of
the retreatment period compared to 89% (95/107) of patients who
didnotrelapseduringthewithdrawalperiod[32].UsingPASI75as
a secondary endpoint, the investigators found that 83% of patients
who had relapsed during the withdrawal period achieved PASI 75
bytheendoftheretreatmentperiod,comparedto93%ofthosewho
did not relapse [32].
Adalimumab Safety Data
Safety data from the off-label adalimumab regimens were
recorded whenever available and are can be found in Table S7.
In the aforementioned studies, there were no reports of rebound
after withdrawal of adalimumab and no cases of non-melanoma
skin cancer, demyelinating disease, or lupus-like syndrome
through 60 weeks of investigation [17,31,32].
After dose escalation to 40 mg QW adalimumab therapy,
Gordon et al. reported one case (1/50) of recent-onset latent TB
infection and one death (1/50) due to cerebrovascular accident in
the 40 mg QW group and one case of coccidiomycosis (1/97) in
the 40 mg EOW group [31]. With regard to malignancies, there
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to two malignancies (2/97) in the 40 mg EOW group [31].
Menter et al. reported aggregate safety data for the 52-week
study period and did not attribute AEs specifically to the
withdrawal-retreatment phases [17]. During the 16 week retreat-
ment period with 285 patients, Papp et al. reported one malignant
melanoma in situ, two serious infections (pneumonia and hepatitis
C), and seven serious AEs [32]. Specifically, the serious AEs were
coronary artery disease, abdominal adhesions, umbilical hernia,
chest discomfort, nephrolithiasis, and fracture of humerus [32].
Adalimumab Anti-Drug Antibodies
No anti-adalimumab antibody (AAA) analyses were reported for
adalimumab dose escalation trials. Although withdrawal-retreat-
ment phases were included in the Menter et al. study, the authors
reported aggregate AAA data for the 52-week study period and
did not specify AAA in the withdrawal-retreatment phase [17].
During the 52-week period, 8.8% (73/825) of patients treated with
at least one dose of adalimumab had detectable AAAs at least once
[17]. A subanalysis showed that 3/7 positive AAA patients
compared with 65/233 (27.9%) negative AAA patients lost
adequate response during adalimumab withdrawal [17].
Papp et al. reported that after a median period of 141 days of
withdrawal, 6% (17/275) of patients tested positive for AAAs [32].
During retreatment, positive AAA samples decreased to 1% (3/
264) after 12 weeks and increased to 2% (4/262) at 16 weeks. A
sub-analysis of patients who relapsed during the withdrawal period
showed that, among those who achieved a PGA score of ‘‘clear’’ or
‘‘almost clear’’ during retreatment, 4% (5/119) had positive AAAs;
in comparison, in those who failed to achieve a PGA score of
‘‘clear’’ or ‘‘almost clear’’ during retreatment, 15% (8/55) had
positive AAA [32]. The authors concluded that the presence of
AAAs is associated with increased risk of failure to re-achieve
efficacy following treatment discontinuation and relapse [32]. In a
prospective observational cohort study (n=29), Lecluse et al.
similarly observed that AAAs in psoriasis patients are associated
with lower serum adalimumab trough concentrations and lack of
adequate response [33]. Of note, in rheumatoid arthritis patients,
the development of AAAs is associated with lower serum
adalimumab concentrations, discontinued treatment, higher
disease activity during treatment, and fewer instances of disease
remission during 3 years of follow-up [34].
Infliximab FDA-Approved Dosing Regimen
Infliximab is a chimeric monoclonal antibody to TNF-a that acts
to neutralize soluble TNF-a and block membrane bound TNF-a
[35]. This TNF-a inhibitor is administered by intravenous (IV)
infusion. Infliximab is indicated for the treatment of psoriasis in a
weight-based dosing regimen of 5 mg/kg at weeks 0, 2 and 6, then
every 8 weeks [35]. Table S3 presents the compiled outcome data
foroff-labeldosingregimenswithinfliximabfromfourpublications.
Efficacy of Infliximab Off-Label Dosing Regimens
Efficacy of Infliximab Dose Escalation. One clinical trial
specifically investigated dose intensification with infliximab in 33
patients [36]. In a controlled trial comparing an escalated dose of
10 mg/kg IV infliximab versus the standard dose of 5 mg/kg IV
infliximab administered at weeks 0, 2, and 6, Chaudhari et al found
that PASI 75 was achieved by 73% of patients dosed at 10 mg/kg
compared to 82% of those dosed at 5 mg/kg at week 10 [36].
Efficacy of Infliximab Withdrawal and Retreatment. A
review of the literature identified three controlled trials that
investigated infliximab withdrawal and retreatment in adult
psoriasis patients [37–39]. Gottlieb et al. conducted a 16 week
open-label study at the conclusion to the aforementioned dose
escalation study to investigate withdrawal and retreatment with
10 mg/kg IV infliximab and 5 mg/kg IV infliximab [39].
‘‘Responders’’ to initial treatment (PGA ‘‘good,’’ ‘‘excellent,’’ or
‘‘clear’’) with 10 mg/kg or 5 mg/kg IV infliximab were withdrawn
and monitored for disease relapse, defined as loss of at least half of
the improvement in PASI at week 10. At the time of relapse,
patients were treated with a single-dose infusion of their originally
randomized dose. The authors reported that patients in the 5 mg/
kg group began to lose response after 8 weeks of drug withdrawal
compared to 12 weeks for the 10 mg/kg group [39].
In EXPRESS II, Menter et al. evaluated continuous versus
interrupted treatment with IV infliximab dosed at 3 mg/kg or
5 mg/kg [37]. All patients received infliximab 3 mg/kg or 5 mg/
kg at weeks 0, 2, and 6. From week 6 through week 14, all patients
entered a withdrawal period. At week 14, the patients were re-
randomized to continuous infusions of infliximab at 8-week
intervals, or interruption with retreatment at the originally
randomized dose upon loss of PASI 75. At week 10, during the
withdrawal period, 70.3% of patients on 3 mg/kg and 75.5% of
patients on 5 mg/kg achieved PASI 75. At week 50, PASI 75 was
achieved by 43.8% of patients on 3 mg/kg every-8-weeks, 54.5%
of those on 5 mg/kg every-8-weeks, 25.4% of patients on 3 mg/kg
interrupted treatment, and 38.1% of those on 5 mg/kg interrupt-
ed treatment [37]. Similar outcomes were observed using
proportion of patients achieving PGA scores of ‘‘clear’’ (1) or
‘‘excellent’’ (2) at weeks 10 and 50. At week 10, 69.8% of patients
receiving 3 mg/kg and 76.0% of patients receiving 5 mg/kg
achieved a PGA score of 1 or 2. In comparison, at week 50, 46.9%
of patients dosed at 3 mg/kg every-8-weeks, 58.2% of those at
5 mg/kg every-8-weeks, 31.7% on 3 mg/kg interrupted treat-
ment, and 42.1% on 5 mg/kg interrupted treatment achieved a
PGA score of 1 or 2 [37]. The authors reported that the most
common time interval for intermittent infusions was 4 to 8 weeks
[37].
Gottlieb et al. examined the effect of a single additional dose of
infliximab after a 20-week withdrawal period [38]. At the study
initiation, all patients were administered 3 mg/kg or 5 mg/kg IV
infliximab at weeks 0, 2, and 6 [38]. From week 6 through
week 26, all patients were withdrawn from infliximab treatment.
During the withdrawal period at week 10, PASI 75 was achieved
by 71.9% of patients on 3 mg/kg and 87.9% of patients on 5 mg/
kg. At week 26, patients with PGA of ‘‘moderate’’ or ‘‘severe’’
disease (114/198) were eligible for a single additional IV infusion
of the originally assigned dose of infliximab. At week 30, a PGA
score of ‘‘clear,’’ ‘‘minimal,’’ or ‘‘mild’’ was achieved by 38% of
those retreated with one single 3 mg/kg infusion and 64% of those
retreated with one single 5 mg/kg infusion of infliximab [38].
Infliximab Safety Data
Safety data from the off-label infliximab regimens were
examined whenever available and can be found in Table S8.
In the dose escalation trial, one case (1/11) of pneumonia was
reported in the 10 mg/kg group and one dental abscess (1/11) was
reported in the 5 mg/kg group [36]. In the withdrawal and
retreatment study by Gottlieb et al, serious infections were
reported in three (3/11) patients in the 10 mg/kg group, two
(2/11) patients in the 5 mg/kg group, and two (2/11) patients in
the placebo group [39]. During the induction phase of EXPRESS
II, one case (1/313) of TB was reported in the 3 mg/kg group.
During the withdrawal-retreatment phase, another case of TB was
reported in the 5 mg/kg interrupted treatment group [37]. In the
same study, the authors noted three cases (3/835) of lupus-like
syndrome during the 50-week study period (one in placebo and
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the EXPRESS II study, one case of peripheral neuropathy was
reported with an unspecified dose of infliximab [37]. From the
aforementioned study by Gottlieb et al., one case (1/99) of sepsis
was reported in a patient receiving 5 mg/kg infliximab [38].
Infliximab Anti-Drug Antibodies
In EXPRESS II, anti-infliximab antibodies were detected in 69/
145(51.5%)patientsinthe3 mg/kgevery-8-weektreatmentgroup,
60/148 (46.2%) in the 3 mg/kg interrupted treatment group, 49/
148 (35.8%) in the 5 mg/kg every-8-week group, and 59/149
(41.5%) in the 5 mg/kg interrupted treatment group [37]. The
investigators reported that a majority (61.1%) of titers were ,1:40
[37]. Gottlieb et al. reported that 21/76 (27.6%) in the 3 mg/kg
patientshadantibodiestoinfliximab,comparedto17/87(19.5%)in
the 5 mg/kg group [38]. Infusion reactions were reported in 9/38
(24%) patients with antibodies through week 26, compared to 25/
116 (22%) patients with no detectable antibodies [38].
Ustekinumab FDA-Approved Dosing Regimen
In 2009, ustekinumab, a fully human monoclonal antibody that
binds p40 subunit of IL-12 and IL-23 was approved for the
treatment of moderate-to-severe psoriasis [40]. Ustekinumab is
administered based on weight at 45 mg (#100 kg) or 90 mg
(.100 kg) by SC injection at weeks 0 and 4, and then every 12
weeks thereafter [40]. Outcomes for off-label dosing regimens with
ustekinumab in two trials are presented in Table S4.
Efficacy of Ustekinumab Off-Label Dosing Regimens
Efficacy of Ustekinumab Dose Escalation. In a dose
escalation study, Papp et al. investigated the effect of dose
intensification with ustekinumab in partial responders [21].
Specifically, patients achieving between PASI 50 and PASI 75
response at week 28 of standard dose ustekinumab (158/821) were
re-randomized to continue dosing at 45 mg or 90 mg every 12
weeks or shorten the dosing interval to every 8 weeks [21].
Between weeks 40 and 52, all patients underwent four study visits.
The mean number of visits that patients achieved PASI 75 was
used as an outcomes measure. In patients receiving every-8-week
dosing of 45 mg or 90 mg ustekinumab, the mean number of visits
with PASI 75 was 1.75 visits, compared to 1.56 visits in patients
dosed every 12 weeks (p=0.468) [21]. Specifically, in the 45 mg
group, the mean number of visits with patients achieving PASI 75
was 1.13 in the every-8-week dosing compared to 1.54 in the
every-12-week dosing group (p=0.21). In the 90 mg group, the
mean number of visits with patients achieving PASI 75 was 2.63 in
the every-8-week dosing compared to 1.58 in the every-12-week
dosing group (p=0.014) .[21].
Efficacy of Ustekinumab Withdrawal and Retreat-
ment. One study investigated ustekinumab withdrawal and
retreatment upon loss of responder status [20]. Leonardi et al.
studied 76 weeks of treatment comparing maintenance therapy to
interrupted treatment to determine time to loss of response [20].
Patients were randomly assigned to receive ustekinumab 45 mg or
90 mg at standard dosing intervals until week 40. At week 40, the
patients who achieved PASI 75 were re-randomized to
maintenance treatment or withdrawal of ustekinumab.
Retreatment for the withdrawal group was administered upon
loss of PASI 75 response. The median time to loss of response in
the withdrawal group was 15 weeks or nearly 4 months [20]. Of
the 195 patients who reinitiated ustekinumab after the withdrawal
period, 167 (85.6%) achieved PASI 75 within 12 weeks of
reinitiating therapy [20].
Ustekinumab Safety Data
Safety data from the off-label ustekinumab regimens were
examined whenever available and can be found in Table S9.
During the dose escalation phase by Papp et al., one (1/77)
cutaneous malignancy and one (1/77) non-cutaneous malignancy
were reported in the every-8-week dosing group without specified
dose [21]. Two (2/77) serious AEs were reported in the every-8-
week dosing group without specified dose. One (1/81) serious
infection and six (6/81) serious AEs were reported in the every-12-
week dosing group without specified dose [21].
During the withdrawal phase of the study by Leonardi et al.,
one (1/160) non-cutaneous cancer was reported in the interrupted
treatment group and two (2/161) cutaneous cancers were reported
in the maintenance therapy group [20]. The authors also reported
two (2/160) serious infections and seven (7/160) serious AEs in the
interrupted treatment group and one (1/161) serious AE in the
maintenance group during the randomized withdrawal phase [20].
Ustekinumab Anti-Drug Antibodies
In the dose intensification study by Papp et al., anti-drug
antibodies were found in 12.7% (20/158) of partial responders and
2.0% (12/589) of PASI 75 responders. The authors determined
that most antibodies were neutralizing [21]. Overall, 5.4% (65/
1202) of all patients receiving ustekinumab in the study developed
antibodies [21]. In the study containing withdrawal-retreatment
phases, anti-ustekinumab antibodies were found in 5.1% (38/746)
of patients_ENREF_20 [20]. The majority of patients had low
titers of less than 1:320 [20].
Alefacept FDA-Approved Dosing Regimen
Alefacept is a recombinant dimeric fusion protein that consists
of the extracellular CD2-binding portion of the human leukocyte
function antigen-3 (LFA-3) linked to the Fc portion of the human
IgG1 [41]. In psoriasis, activation of T lymphocytes involves
interaction between LFA-3 on the antigen-presenting cells and
CD2 on T lymphocytes. Alefacept binds to CD2 on lymphocytes,
thereby inhibiting the LFA-3/CD2 interaction. Alefacept inter-
feres with the activation and proliferation of memory effector T
lymphocytes [41]. Alefacept is approved for dosing at 15 mg by
once weekly intramuscular (IM) injection for a course of 12 weeks
[41]. Repeated rounds of 12-week treatment periods are
considered for patients only after a 12-week drug holiday provided
that CD4+ T lymphocyte counts are within the normal range [41].
We will define a retreatment cycle as 12 weeks of treatment with
alefacept, followed by 12 weeks of drug-free observation. Table
S5 summarizes the outcome data for off-label dosing regimens
with alefacept from seven clinical studies.
Efficacy of Alefacept Off-Label Dosing Regimens
Efficacy of Alefacept Dose Escalation. Two trials that
studied dose escalation regimens with alefacept were identified in a
search of the literature [42,43]. Gribetz et al. compared efficacy
and safety of standard 12-week versus extended 16-week therapy
with 15 mg IM alefacept in 20 patients [42]. After an initial 12
weekly dosing of alefacept, cohort 1 received 4 weekly doses of
placebo (standard dosing), whereas cohort 2 received 4 additional
weekly doses of alefacept (extended 16-week group). The mean
percentage change in PASI from baseline during weeks 12 to 24
was 2% for cohort 1 compared to 26% for cohort 2 (p=,0.05)
[42]. PASI 75 and PASI 50 were achieved by 10% and 60% of
patients in cohort 1, respectively, and 30% and 60% of patients in
cohort 2 at any time during weeks 12 and 24 [42]. At week 24,
PGA ‘‘clear’’ or ‘‘almost clear’’ was achieved in 0/10 (0%) of those
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investigated treatment escalation in two off-label regimens [43].
Cohort 1 received 30 mg IM alefacept for 6 weeks followed by 6
weeks of 15 mg IM alefacept, and cohort 2 received 30 mg IM
alefacept for 12 weeks. At week 14 of the study, 1/8 (12.5%)
patients in cohort 1 and 1/8 (12.5%) in cohort 2 achieved PASI 75
[43].
Efficacy of Alefacept Dose Reduction. Ortonne et al. and
Lebwohl et al. compared alefacept 15 mg IM once weekly, 10 mg
IM once weekly, or placebo in 507 adult psoriasis patients [44,45].
At week 2 of the drug holiday, after 12-weeks of treatment, PASI
75 was achieved by 21% of patients receiving 15 mg alefacept,
12% of those on 10 mg alefacept, and 5% of those receiving
placebo [44].
EfficacyofAlefaceptIntermittentTreatment. Fourstudies
investigated intermittent treatment with alefacept defined as drug
withdrawal and retreatment in consecutive cycles [22,46–48].
Krueger et al. compared two cycles of 7.5 mg IV alefacept,
defined as cohort 1, to one cycle of 7.5 mg IV alefacept followed
by one cycle of placebo, defined as cohort 2 [22]. PASI 75 at week 2
of withdrawal during the second treatment cycle was achieved by
23%of cohort 1compared to7%of cohort 2[22]. Overall response
rates(ORRs)weredefinedasachievingPASI75,PASI50,oraPGA
score of ‘‘clear’’ or ‘‘almost clear’’ during any time in a 24-week
treatment and follow-up cycle. After one treatment cycle, members
of cohorts 1 and 2 reported ORRs to be 28%(PASI 75), 56%(PASI
50),and23%(PGA‘‘clear’’or‘‘almostclear’’)[22].Aftertwocycles,
cohort 1 achieved higher ORRs, 37% (PASI 75), 64% (PASI 50),
and 30% (PGA ‘‘clear’’ or ‘‘almost clear’’), compared to cohort 2
who achieved ORRs of 19%, 49%, and 18% after 12 weeks of
placebo (p=0.035 for PGA score ‘‘clear’’ or ‘‘almost clear’’) [22].
The median duration of PASI 50 maintenance in cohort 2 patients
who achieved PASI 75 anytime during the initial treatment cycle
was 216 days, or over 7 months [22].
Three open-label studies evaluated retreatment cycles with
alefacept for up to three treatment cycles [46–48]. Each study
enrolled patients who had previously received treatment with one
or two cycles of alefacept in Phase II or III drug trials and who
presented with disease severity investigators determined required
systemic therapy. Lowe et al. administered 7.5 mg IV alefacept to
174 patients who had previously received alefacept in a Phase II
RCT [46]. Two weeks after completion of the 12-week alefacept
administration, PASI 75 was achieved by 16% of patients in cycle
1 compared to 18% of patients at the same point during treatment
cycle 2 [46]. Of note, almost half (50/107) patients experienced
superior ORRs during cycle 2 compared to cycle 1 [46]. Gordon
et al. examined the median duration to loss of response, defined as
PGA ‘‘mild’’ or more severe, in patients treated with 15 mg IM
alefacept [48]. The authors found that patients who achieved
PASI 75 during initial treatment maintained PASI 50 for a median
duration of 209 days or approximately 7 months. Upon loss of
response, patients were retreated with 15 mg IM alefacept for
12 weeks. At the conclusion of the 24 week study, 43% of patients
had achieved PASI 75 upon retreatment with alefacept [48].
Roberts et al. investigated retreatment cycles with 15 mg IM
alefacept in patients who did not receive PGA ‘‘clear’’ after each
cycle of treatment [47]. PGA ‘‘clear’’ or ‘‘almost clear’’ was
achieved by 16%, 22%, and 19% of patients at week 2 after the
12-week treatment completion for cycles 1, 2, and 3 respectively
[47].
Alefacept Safety Data
Safety data from the off-label alefacept regimens were examined
whenever available and can be found in Table S10. In a dose
escalation trial, Gribetz et al. reported two (2/10) serious infections
in cohort 1, including one case of cellulitis and one case of
Helicobacter pylori, and no (0/10) serious infections in cohort 2 [42].
In the second dose escalation study, Cafardi et al. reported two
cases (2/8) of morphological change from plaque psoriasis to
erythroderma in cohort 1 [43]. One patient with erythroderma
was hospitalized during the 15 mg IM alefacept phase [43]. One
intermittent treatment study reported five internal and cutaneous
malignancies (5/174) in unspecified treatment cycles [46] and
another reported 16 (16/183) internal and cutaneous malignancies
in unspecified treatment cycles [47]. Specifically, Lowe et al. stated
that there were no excess malignancies in alefacept-treated
patients than untreated individuals [46]. Lowe et al. reported
two serious infections, including one case (1/174) of pneumonia in
retreatment cycle 1 and one case (1/107) of herpes zoster in
retreatment cycle 2 [46]. Roberts et al. reported 15 serious
infections, including one case of mycoplasmal tracheobronchitis
and 14 cases of herpes simplex: four cases (4/175) in cycle 1, six
cases (6/121) in cycle 2, and four cases (4/88) in cycle 3 [47].
Alefacept Anti-Drug Antibodies
Anti-alefacept antibodies were detected in ,1% to 6% of
patients receiving the study drug for up to 5 retreatment cycles
with no significant increase in antibodies reported with retreat-
ment [22,45–48]. One study reported decreases in anti-drug
antibodies with retreatment [46]. Low titers were observed with
anti-drug antibodies [22,45–48] and were not associated with
hypersensitivity reactions [22,45].
Discussion
Psoriasis is a chronic, relapsing and remitting disease that
necessitates long-term treatment. In clinical practice, off-label
dosing regimens are relevant and central to individualized therapy.
For example, patients that exhibit sub-optimal response to
standard biologic therapy may require dose intensification,
whereas invasive surgery, infectious episodes, or changes in
healthcare coverage may require temporary cessation of a biologic
therapy. Therefore, it is important to synthesize the highest-quality
available evidence for off-label regimens to inform real-world
clinical practice. No guidelines exist to date for off-label use of
biologic therapy in dose escalated, reduced, interrupted, or
intermittent regimens. Through a systematic review, we synthe-
sized data from 23 trials that investigated non-standard treatments
with etanercept, adalimumab, infliximab, ustekinumab, and
alefacept for moderate-to-severe plaque psoriasis in adults.
Dose Escalation Considerations
Most dose escalation trials were performed in patients who did
not exhibit full response to standard biologic dosing regimens. For
etanercept dose escalation, data support that dose escalation to
50 mg BIW among non-responders improves PASI 50 response
after 12 weeks of dose intensification [26] and improves PASI 75
response for at least 60 weeks of treatment [25]. With regard to
adalimumab dose escalation, in non-responders to standard
therapy, dose escalation to 40 mg QW improves clinical response
from 0% achieving PASI 50 to 40% achieving PASI 50 after
36 weeks of treatment [31]. Dose escalation with infliximab at
10 mg/kg did not produce superior results to standard therapy,
with 73% of patients on 10 mg/kg achieving PASI 75 compared
to 82% of patients on 5 mg/kg [36]. Data from one ustekinumab
dose escalation study suggests that partial responders who escalate
dosing to every 8 weeks experience greater psoriasis control for at
least 28 weeks [21]. With regard to alefacept dose escalation,
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resulted in greater efficacy as measured by PASI 75 and PGA than
the standard 12-week dosing [42]. Larger studies are necessary to
further characterize the degree of efficacy gained through the
varying dose escalation regimens and duration of dose escalation.
Dose Reduction Considerations
All dose reduction studies found that decreased doses of biologic
therapy resulted in worse outcomes compared to standard biologic
treatment [16,44,45]. Reduction of etanercept induction and
maintenance treatment to 25 mg QW and 25 mg BIW resulted in
decreased PASI improvement compared to standard dosing [16].
Alefacept dose reduction from 15 mg IM to 10 mg IM resulted in
smaller proportion of patients achieving PASI 75 [44,45]. Overall,
treatment with FDA-approved dosing regimens resulted in
superior efficacy compared to dose reduction regimens.
Withdrawal and Retreatment Considerations
The preponderance of data in Tables S1, S2, S3, S4, S5
suggests that continuous therapy is recommended for all biologics
reviewed here with the exception of alefacept. In most studies, only
responders (usually defined as patients achieving PASI 75 or PGA
‘‘clear’’ or ‘‘almost clear’’) were eligible to enter the withdrawal
and retreatment periods. Thus, much of the withdrawal-retreat-
ment data cannot be directly extrapolated to non-responders.
Studies also used different definitions for disease relapse as well as
efficacy outcome measures for retreatment. Specifically, for
patients on etanercept, it took a median of 85 days for responders
to relapse (loss of PASI 75), and 52% of the initial responders
regained PASI 75 with retreatment [27]. For those on adalimu-
mab, nearly 5 months of treatment withdrawal was necessary for
responders to relapse to at least moderate disease, and 87% of
patients regained PASI 75 after retreatment [32]. Due to the
significant concern with anti-drug antibody formation, continuous
infliximab therapy was necessary to maintain psoriasis control.
While some clinicians add methotrexate to infliximab to prevent
the formation of anti-drug antibody and to increase efficacy, large
RCTs are necessary to determine potential additive efficacy from
methotrexate addition. Patients on ustekinumab lost PASI 50
response after a median of 15 weeks of withdrawal, and 85.6% of
initial responders regained PASI 75 [20]. Alefacept is approved as
intermittent treatment where treatment cycles lasting 12-weeks are
punctuated with a 12-weeks of drug-free period [22,46–48].
Safety Considerations
Safety considerations are important in assessing benefit-risk
profile of administering biologic therapy to eligible psoriasis
patients. Challenges in assessing safety issues include low event
rates, lack of a comparison group for some open-label extension
studies, inconsistent reporting methods, and long lead-time
expected for certain types of adverse events (such as malignancy).
For standard dosing regimen of anti-TNF agents, a meta-analysis
studying the association of short-term use of anti-TNF agents with
infections and malignancies showed that there was a small risk of
overall infection and no increased risk of serious infection or
malignancy [49]. A recent meta-analysis studying adverse
cardiovascular events found no significant differences in the
MACE in psoriasis patients receiving etanercept, adalimumab,
infliximab, or ustekinumab [50].
Most studies involving off-label dosing regimens of biologic
agents enrolled a smaller number of participants, and therefore
adverse event rates were small and difficult to interpret.
Furthermore, the aforementioned challenges in reporting safety
events likely exist to a greater degree in off-label dosing studies.
While this systematic review synthesized detailed rates of adverse
events for the off-label dosing regimen, further large studies are
necessary to understand whether safety issues exist with dose
intensification, reduction, or withdrawal-retreatment.
Summary
Off-label dosing of biologics for the treatment of moderate-to-
severe psoriasis is a clinically relevant and important issue in real-
world practice settings. This is the first systematic review to date
that examined off-label dosing regimens of the FDA-approved
biologic agents etanercept, adalimumab, infliximab, ustekinumab,
and alefacept for moderate-to-severe psoriasis. In general, the
preponderance of data suggests that continuous treatment with
anti-TNF agents and anti-IL12/23 agent are necessary for
maintenance of disease control. Among non-responders, dose
escalation with etanercept, adalimumab, and ustekinumab usually
results in greater efficacy than standard dosing. Safety data on off-
label dosing regimens are limited in the examined biologics, and
larger studies are necessary to determine risks associated with
varying dosing regimens.
In patients where interrupted therapy is considered, such as
those experiencing active infections, undergoing invasive surgeries,
or desiring to discontinue treatment in pregnancy, the clinician
needs to carefully weigh the benefit-risk ratio of interrupted
therapy. Clinicians need to consider whether an interruption is
necessary, how the duration of interruption may affect subsequent
treatment efficacy, and possible disease exacerbation during
interruption. Therefore, the decision to use off-label dosing needs
to account for both benefits and risks and be individualized to
patients’ disease severity, quality of life, and existence of
comorbidities.
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